Pharmaceutical Regulator Comparison
39 Pharma Regulators,
One Reference Tool.
Cross-reference named patient pathways, hospital procurement bodies and key documentation requirements for the regulators that govern UK pharmaceutical export across GCC, Levant, Africa, Europe, CIS and Asia. Built and maintained by Euro Biom, an MHRA WDA-licensed UK pharmaceutical wholesaler.
MHRA WDA Licence No. WDA(H) 59239
39
Regulators covered across 5 regions
6
Data points per regulator
40+
Export markets covered
2026
Reviewed October 2026
39 regulators
| Regulator ▲▼ | Country / Region ▲▼ | Region ▲▼ | Named Patient Pathway ▲▼ | Hospital Procurement ▲▼ | Country Page |
|---|
How to Use This Comparison
A practical lens
for UK pharmaceutical export.
for UK pharmaceutical export.
This tool was built as a reference for UK-licensed export planning. The pattern across regulators matters more than any single cell, and the value lies in spotting the route that fits the deal.
UK Exporter Perspective
Every entry is read through the lens of a UK MHRA-licensed wholesaler. We highlight the documents each regulator typically requests and the export documents we can supply.
Registration vs Named Patient
Full registration usually takes far longer than a named patient or special import route. The right column for your deal depends on whether the medicine is recurring stock or a single clinical case.
Hospital Procurement Entry
Centralised systems like NUPCO, KEMSA and Hamad Medical Corporation aggregate volume but require pre-qualification. Fragmented markets like the UAE run parallel routes across EDE, DHA and DOH, with hospital groups such as SEHA buying separately.
Recent Regulator Changes
Regulators change. The UAE has moved federal medicines work to the Emirates Drug Establishment, and Morocco, Senegal and Côte d'Ivoire now have dedicated agencies. The table uses the current names.
Frequently Asked Questions
Cross-Regulator Questions,
From UK Exporters.
From UK Exporters.
Common questions from regulatory affairs teams, hospital procurement leads and UK manufacturers planning international supply.
Which regulators accept English-language Certificate of Pharmaceutical Product (CPP)?
Most Anglophone and Commonwealth markets accept English-language CPP issued by the UK MHRA. This includes Nigeria, Kenya, Ghana, Uganda, Tanzania, Rwanda, South Africa, Zimbabwe, India, Pakistan and Bangladesh. GCC regulators including SFDA, EDE, MOPH and NHRA generally expect Arabic text on labels and leaflets, so buyers should confirm the current labelling and document language rules with the relevant regulator. Buyers in francophone Africa and the EU should confirm with the regulator whether certified translation or local-language literature is required.
Which markets have NUPCO-style centralised hospital procurement?
Saudi Arabia operates NUPCO as the strongest centralised aggregator. Kuwait centralises through the Ministry of Health, with tenders approved by the Central Agency for Public Tenders. Qatar centralises through Hamad Medical Corporation. UAE splits across emirate-level authorities (DHA and DOH) and federal EDE, with SEHA as the main Abu Dhabi public hospital purchaser. In Africa, Kenya runs KEMSA, Tanzania uses MSD, Uganda uses NMS. France operates through GHT regional groupings, Germany through individual hospital tenders, Ireland through the HSE.
Which regulators allow named patient supply without prior product registration?
Established routes exist in France (ANSM accès compassionnel), Germany (pharmacy import under section 73(3) AMG), the Netherlands (IGJ permission on a doctor's declaration), Belgium (FAMHP compassionate use and medical need programmes) and Ireland (exempt medicinal products notified to HPRA). Saudi Arabia (SFDA) and the UAE (EDE, DHA) operate named patient routes for life-saving and rare-disease medicines. Most major African and Asian regulators have named patient frameworks, but documentation thresholds vary considerably.
How long does full pharmaceutical registration typically take by region?
Timing varies with the product, the route and the regulator's backlog, and published figures often conflict. Treat any quoted range as indicative, and confirm the current position with the regulator or the local registration holder.
Do all GCC regulators accept GCC central registration?
The GCC operates a Central Registration Procedure managed by the Executive Board. Approval through the central pathway provides registration in member states subject to each national authority adopting the central decision. In practice, most companies still pursue national registration alongside central, particularly with SFDA, EDE and MOPH, because pricing decisions, hospital tender entry and distribution licences are administered separately at national level.
Which African regulators are part of the African Medicines Agency framework?
The African Medicines Agency is being established, with member-state ratifications progressing, and Rwanda hosts it. It does not yet operate a single registration, so buyers still work with the national regulator in each market.
What should buyers expect on cold chain at customs?
Requirements are set market by market. For temperature-sensitive lines, expect the importer or regulator to ask for temperature records covering the shipment, and agree what is needed before dispatch. Where receiving infrastructure is limited, shipment monitoring matters more.
Have a regulator-specific question?
Send us the medicine, country and clinical setting. We respond the same working day with availability and the UK-side document set we can supply. No obligation at quote stage.
Same-day response, Mon to Fri 09:00-18:00 UK time